Journal
DIABETES OBESITY & METABOLISM
Volume 19, Issue 6, Pages 906-908Publisher
WILEY
DOI: 10.1111/dom.12885
Keywords
antidiabetic drug; GLP-1 analogue; incretin therapy; liraglutide; meta-analysis; type 2 diabetes
Categories
Funding
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Amgen
- Eli Lilly
- SD/Merck
- Novo Nordisk
- Sanofi
- Zealand Pharma
- Novo Nordisk Fonden [NNF16OC0020224, NNF15OC0016230, NNF12OC1015904] Funding Source: researchfish
Ask authors/readers for more resources
Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose upon doctors the obligation to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9347 GLP-1RA-treated and 9353 placebotreated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increases the risk of AP in patients with type 2 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available